At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 111 enrolled
Drug / intervention
Paliperidone ERdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Jul 1, 2004·Updated Jun 8, 2011
In Brief
A Phase 3 clinical trial evaluating Paliperidone ER for Schizophrenia. Completed, enrolled 111 participants.
Detailed Summary
The purpose of this study is to determine the efficacy (effectiveness) and safety of paliperidone ER compared with placebo in the prevention of recurrence of symptoms of schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2004
First PostedJul 2004
Study CompletionAug 2005
TodayJul 2026
First PostedJul 1, 2004
Enrollment StartMar 1, 2004
Study CompletionAug 1, 2005
TodayJul 2, 2026
Posted 22.0 years ago
Interventions
Paliperidone ERdrug